Combination of adenovirus vector and subunit protein elicits a robust immune response against the SARS-CoV-2 Omicron variant
Chunjun Ye·Xiawei Wei·Yishan Lu·Danyi Ao·Xiangrong Song·Jie Shi·Xiya Huang·Yanyan Liu·Guangwen Lu·Weiqi Hong·Yu Zhang·Jiong Li·Zhiruo Song·Ping Cheng·Yi Zhou
The rapid and ongoing emergence of SARS-CoV-2 variants has progressively reduced the protection offered by current vaccines, underscoring the urgent need for novel vaccine strategies. In this study, we designed a two-component vaccine in which one component is an adenoviral vector encoding the Omicron XBB.1.5 spike protein (Ad5<sub>XBB.1.5</sub>), and the other component is a self-assembling trimeric receptor-binding domain protein (RBD<sub>XBB.1.5</sub>-HR or RBD<sub>JN.1</sub>-HR). This platfo